Literature DB >> 16983529

[Salvage radical prostatectomy].

R E Hautmann1.   

Abstract

BACKGROUND: Following external beam radiation and interstitial radiation for prostate cancer, between 30% and 50% of the patients experience locoregional recurrence of their cancer. Although radical salvage prostatectomy is a secondary treatment option with curative intent, so far only a few hundred patients (<2%) worldwide have undergone this operation. The subject of this paper is a review of the world literature with reference to the frequency with this operation is performed and the technique, and also the prospects of success and possible complications. PATIENTS AND METHODS: After radiotherapy, approximately 30% of biopsies are positive. Nonetheless, only 536 cases of salvage radical prostatectomy had been reported in the world literature up to 2005. The diagnosis of a local recurrence was always confirmed by rectal punch biopsy, pelvic CT and bone scintigraphy. Salvage radical prostatectomy with or without nerve sparing, with pelvic lymphadenectomy and, in some patients with cystectomy plus urinary diversion was the operative treatment applied.
RESULTS: Following secondary treatment after radiotherapy (RT), three parameters have been consistently identified as predictors of local failure: PSA nadir, time to nadir and PSA doubling time; clinical stage and type of first-line treatment are not helpful in predicting failure. The 5-year biochemical relapse-free survival rates are 77%, 71% and 28% for stages pT2, pT3a and pT3b/pN1, respectively. The success rate for salvage radical prostatectomy is thus similar to that for de novo radical prostatectomy for the same stages. In the past salvage radical prostatectomy following radiotherapy had a high complication rate.
CONCLUSIONS: A salvage radical prostatectomy with curative intent is a radical prostatectomy following radiotherapy also performed with curative intent. The reasons for the few literature reports of salvage RPX are: (1) oncological misgivings (too long a period of observation of PSA by the radiation oncologist/urologist; (2) misgivings to do with surgical technique, as the operation is technically challenging and involves a high risk of complications, especially incontinence. In recent times the comorbidity rate has become acceptable in cases in which the indications have been correctly observed. We believe that salvage prostatectomy should be considered only for patients in good general health whose life expectancy is over 10 years and who have recurrent cancer confirmed by punch biopsy 1 year or longer after the completion of radiotherapy and whose cancer was initially in an early (T1-2) clinical stage before their radiotherapy. Ideally, serum PSA should be less than 10 ng/ml both initially (before radiotherapy) and before salvage surgery. In addition, patients should be highly motivated and able to accept the surgical morbidity (50% incontinence rate).

Entities:  

Mesh:

Year:  2006        PMID: 16983529     DOI: 10.1007/s00120-006-1181-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis.

Authors:  L M Rainwater; H Zincke
Journal:  J Urol       Date:  1988-12       Impact factor: 7.450

2.  Salvage radical prostatectomy for adenocarcinoma of the prostate.

Authors:  I M Thompson; J B Rounder; C R Spence; F R Rodriguez
Journal:  Cancer       Date:  1988-04-01       Impact factor: 6.860

Review 3.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors:  J D Cox; M J Gallagher; E H Hammond; R S Kaplan; P F Schellhammer
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

4.  Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy.

Authors:  Andrew J Stephenson; Peter T Scardino; Fernando J Bianco; Christopher J DiBlasio; Paul A Fearn; James A Eastham
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes.

Authors:  H Zincke
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation.

Authors:  P C Brenner; P Russo; D P Wood; M J Morse; S M Donat; W R Fair
Journal:  Br J Urol       Date:  1995-01

8.  Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate.

Authors:  D R Mador; R P Huben; Z Wajsman; J E Pontes
Journal:  J Urol       Date:  1985-01       Impact factor: 7.450

9.  4-Defect repair of grade 4 cystocele.

Authors:  M H Safir; A E Gousse; E S Rovner; D A Ginsberg; S Raz
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

10.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

Authors:  H Zincke; J E Oesterling; M L Blute; E J Bergstralh; R P Myers; D M Barrett
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  4 in total

Review 1.  [Therapy options in relapsing prostate cancer after external radiation therapy].

Authors:  A Häcker; P Alken
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

2.  [Value of cystoprostatectomy in locally advanced prostate carcinoma].

Authors:  N Zantl; J E Gschwend
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

3.  Extended salvage pelvic lymph node dissection in patients with recurrent prostate cancer.

Authors:  Daniar K Osmonov; Alexey V Aksenov; Annkathrin Boller; Almut Kalz; Diana Heimann; Isa Janssen; Klaus-Peter Jünemann
Journal:  Adv Urol       Date:  2014-02-12

4.  Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer.

Authors:  Rodrigo Donalisio da Silva; Fernando J Kim
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.